205 related articles for article (PubMed ID: 28445193)
1. A Pilot Randomized Trial on Safety and Efficacy of a Novel Topical Combined Inhibitor of Janus Kinase 1/3 and Spleen Tyrosine Kinase for GVHD-Associated Ocular Surface Disease.
Kheirkhah A; Di Zazzo A; Satitpitakul V; Fernandez M; Magilavy D; Dana R
Cornea; 2017 Jul; 36(7):799-804. PubMed ID: 28445193
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
[TBL] [Abstract][Full Text] [Related]
3. Reduced Efficacy of Low-dose Topical Steroids in Dry Eye Disease Associated With Graft-versus-Host Disease.
Yin J; Kheirkhah A; Dohlman T; Saboo U; Dana R
Am J Ophthalmol; 2018 Jun; 190():17-23. PubMed ID: 29572107
[TBL] [Abstract][Full Text] [Related]
4. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
[TBL] [Abstract][Full Text] [Related]
5. A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease.
Abud TB; Amparo F; Saboo US; Di Zazzo A; Dohlman TH; Ciolino JB; Hamrah P; Dana R
Ophthalmology; 2016 Jul; 123(7):1449-57. PubMed ID: 27086024
[TBL] [Abstract][Full Text] [Related]
6. Vision-Related Quality of Life in Patients with Ocular Graft-versus-Host Disease.
Saboo US; Amparo F; Abud TB; Schaumberg DA; Dana R
Ophthalmology; 2015 Aug; 122(8):1669-74. PubMed ID: 26001816
[TBL] [Abstract][Full Text] [Related]
7. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.
Sosne G; Dunn SP; Kim C
Cornea; 2015 May; 34(5):491-6. PubMed ID: 25826322
[TBL] [Abstract][Full Text] [Related]
8. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
[TBL] [Abstract][Full Text] [Related]
9. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
[TBL] [Abstract][Full Text] [Related]
10. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
11. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.
Tauber J; Davitt WF; Bokosky JE; Nichols KK; Yerxa BR; Schaberg AE; LaVange LM; Mills-Wilson MC; Kellerman DJ
Cornea; 2004 Nov; 23(8):784-92. PubMed ID: 15502479
[TBL] [Abstract][Full Text] [Related]
12. Subtarsal Fibrosis Is Associated With Ocular Surface Epitheliopathy in Graft-Versus-Host Disease.
Kheirkhah A; Coco G; Satitpitakul V; Dana R
Am J Ophthalmol; 2018 May; 189():102-110. PubMed ID: 29505774
[TBL] [Abstract][Full Text] [Related]
13. Corneal fluorescein staining and ocular symptoms but not Schirmer test are useful as indicators of response to treatment in chronic ocular GVHD.
Amparo F; Shikari H; Saboo U; Dana R
Ocul Surf; 2018 Jul; 16(3):377-381. PubMed ID: 29763694
[TBL] [Abstract][Full Text] [Related]
14. The effect of an artificial tear combining hyaluronic acid and tamarind seeds polysaccharide in patients with moderate dry eye syndrome: a new treatment for dry eye.
Barabino S; Rolando M; Nardi M; Bonini S; Aragona P; Traverso CE
Eur J Ophthalmol; 2014; 24(2):173-8. PubMed ID: 24030535
[TBL] [Abstract][Full Text] [Related]
15. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation.
Davitt WF; Bloomenstein M; Christensen M; Martin AE
J Ocul Pharmacol Ther; 2010 Aug; 26(4):347-53. PubMed ID: 20653478
[TBL] [Abstract][Full Text] [Related]
16. Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1%D-3-Hydroxybutyrate eye drops for Dry Eye Disease.
Kawakita T; Uchino M; Fukagawa K; Yoshino K; Shimazaki S; Toda I; Tanaka M; Arai H; Sakatani K; Hata S; Okano T; Tsubota K
Sci Rep; 2016 Feb; 6():20855. PubMed ID: 26865350
[TBL] [Abstract][Full Text] [Related]
17. A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study.
Sheppard JD; Wirta DL; McLaurin E; Boehmer BE; Ciolino JB; Meides AS; Schlüter T; Ousler GW; Usner D; Krösser S
Cornea; 2021 Oct; 40(10):1290-1297. PubMed ID: 34481407
[TBL] [Abstract][Full Text] [Related]
18. Ophthalmic cyclosporine use in ocular GVHD.
Lelli GJ; Musch DC; Gupta A; Farjo QA; Nairus TM; Mian SI
Cornea; 2006 Jul; 25(6):635-8. PubMed ID: 17077652
[TBL] [Abstract][Full Text] [Related]
19. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
Donnenfeld ED; Karpecki PM; Majmudar PA; Nichols KK; Raychaudhuri A; Roy M; Semba CP
Cornea; 2016 Jun; 35(6):741-8. PubMed ID: 27055211
[TBL] [Abstract][Full Text] [Related]
20. Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection.
Deuse T; Velotta JB; Hoyt G; Govaert JA; Taylor V; Masuda E; Herlaar E; Park G; Carroll D; Pelletier MP; Robbins RC; Schrepfer S
Transplantation; 2008 Mar; 85(6):885-92. PubMed ID: 18360272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
